LIFT trial of pyridostigmine and low-dose naltrexone
Open Medicine Foundation · 2024 · ClinicalTrials.gov
Indexed 2026-11-12.
Reported findings and study design
No measured outcomes in the accessed disclosure
Four blinded arms test pyridostigmine, low-dose naltrexone, both, or double placebo. Planned titration reaches 60 mg pyridostigmine three times daily and 4.5 mg naltrexone daily in the relevant arms.
Dose, route and schedule
Four blinded arms test pyridostigmine, low-dose naltrexone, both, or double placebo. Planned titration reaches 60 mg pyridostigmine three times daily and 4.5 mg naltrexone daily in the relevant arms.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Results availability | Recruiting at source review. The registry had no posted results. |
The target enrollment and endpoints come from the registry. Function and exercise physiology are planned outcomes.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The target enrollment and endpoints come from the registry. Function and exercise physiology are planned outcomes.
Related publications may cover the same research program or participants.
Source access
Four blinded arms test pyridostigmine, low-dose naltrexone, both, or double placebo. Planned titration reaches 60 mg pyridostigmine three times daily and 4.5 mg naltrexone daily in the relevant arms.
Source reviewed 2026-11-12.
Source type: Trial registration
Citation and original source
Original source: Open Medicine Foundation. LIFT trial of pyridostigmine and low-dose naltrexone ClinicalTrials.gov 2024.
Molekul research summary: https://molekul.io/research/pyridostigmine-naltrexone-lift-protocol. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry